HER2+ Breast Cancer: First- & Second-Line Treatment Insights from MBC Conference 2026
Discussions at the recent Miami Breast Cancer Conference are prompting oncologists to reconsider first-line treatment strategies for HER2-positive breast cancer, potentially shifting established practices. A key focus was the increasing utilization of the combination regimen featuring trastuzumab deruxtecan (Enhertu) plus pertuzumab, and determining the optimal duration of treatment with this approach. These conversations, according to experts, could lead to a significant evolution in how this aggressive form of breast cancer is managed.
Understanding HER2-Positive Breast Cancer
HER2-positive breast cancer is a subtype defined by the presence of an abnormally high level of the human epidermal growth factor receptor 2 (HER2) protein on the surface of cancer cells. The National Cancer Institute explains that this excess HER2 promotes cancer cell growth. Whereas historically challenging to treat, advancements in targeted therapies have dramatically improved outcomes for patients with this diagnosis. Trastuzumab deruxtecan, a relatively new antibody-drug conjugate, delivers a potent chemotherapy directly to HER2-expressing cancer cells, minimizing damage to healthy tissues.
DESTINY-Breast09 and the Shift in First-Line Treatment
The DESTINY-Breast09 trial, referenced by Dr. Paolo Tarantino, has been pivotal in reshaping treatment paradigms. As reported by Healio, this study demonstrated improved progression-free survival with trastuzumab deruxtecan in pretreated HER2-positive breast cancer. The trial enrolled patients who had previously received one or more prior anti-HER2-based regimens. The combination of trastuzumab deruxtecan and pertuzumab is now being considered as a viable first-line option, even for patients who haven’t yet received prior therapy, a move that represents a significant change in approach.
Determining Optimal Treatment Duration
Beyond simply adopting the combination regimen, a central theme at the conference was determining how long patients should continue receiving trastuzumab deruxtecan. The optimal duration remains an area of active investigation. Factors influencing this decision include treatment response, tolerability, and potential for long-term side effects. Dr. Tarantino emphasized that the discussions at the conference helped clarify his thinking on this crucial aspect of patient management.
Second-Line Treatment Strategies for Hormone Receptor-Positive Breast Cancer
The conference also addressed challenges in managing hormone receptor-positive breast cancer, specifically identifying effective second-line treatments for patients whose disease progresses after initial hormone therapy. This represents a complex area, as resistance to hormone therapy is a common occurrence. Researchers explored various strategies, including targeted therapies and chemotherapy regimens, to overcome this resistance and improve patient outcomes. The specific details of these discussions were not elaborated upon in the source material, but highlight the breadth of topics covered at the conference.
Potential Implications and the Evolving Landscape
The shift towards earlier utilization of trastuzumab deruxtecan, as suggested by the discussions at the Miami Breast Cancer Conference, could have far-reaching implications for patients with HER2-positive breast cancer. It may lead to improved disease control, prolonged survival, and enhanced quality of life. However, it’s important to acknowledge that trastuzumab deruxtecan is not without its potential side effects, including interstitial lung disease and liver toxicity. Careful monitoring and management of these side effects are crucial.
Disclosures and Conflicts of Interest
It’s important to note that Dr. Tarantino has disclosed financial relationships with several pharmaceutical companies, including AstraZeneca, Daiichi Sankyo, and others involved in the development and marketing of breast cancer therapies. These disclosures are standard practice in medical conferences and publications, and are intended to ensure transparency and address potential conflicts of interest.
What Comes Next: Ongoing Research and Guidance Updates
The evolving understanding of HER2-positive breast cancer treatment necessitates ongoing research and refinement of clinical guidelines. Future studies will likely focus on identifying biomarkers that can predict which patients are most likely to benefit from trastuzumab deruxtecan, optimizing treatment duration, and developing strategies to mitigate potential side effects. Professional organizations, such as the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN), will continue to review emerging data and update their treatment recommendations accordingly. Patients and their clinicians should stay informed about these updates and engage in shared decision-making to determine the most appropriate treatment plan.